Pharma BD Deal Intelligence
AstraZeneca's $1.8B bet on CinCor Pharma paid off: baxdrostat, the aldosterone synthase inhibitor acquired for its cardiorenal pipeline, hit its Phase III primary endpoint and won FDA approval as BAXFENDY for treatment-resistant hypertension—vindicating the thesis in just over three years.
AstraZeneca acquired CinCor Pharma for $1.8B for hypertension treatment.
AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline with baxdrostat.
CinCor Pharma to be acquired by AstraZeneca for $26/share upfront plus $10 CVR totaling approximately $1.8 billion.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
AstraZeneca acquired CinCor Pharma in February 2023 for approximately $1.8 billion ($26.00/share upfront plus a $10.00/share contingent value right) to add baxdrostat, a first-in-class oral aldosterone synthase inhibitor, to its cardiorenal pipeline. The thesis was validated post-close: the pivotal BaxHTN Phase III trial met its primary endpoint (the 2 mg dose lowered seated systolic blood pressure by 15.7 mmHg from baseline and 9.8 mmHg vs placebo at 12 weeks), the data were published in NEJM and presented at ESC 2025, the US NDA was accepted under Priority Review on 2 December 2025, and on 18 May 2026 the FDA approved baxdrostat as BAXFENDY -- the first aldosterone synthase inhibitor for adults with hypertension inadequately controlled on other antihypertensives.
37M US cases/yr · $18.0B US CKD market (2024) · ~90% Unaware of CKD status
Chronic kidney disease affects ~37 million Americans, with cardiorenal syndrome representing a major driver of morbidity and mortality. SGLT2 inhibitors and finerenone have expanded treatment options, but significant unmet need persists in advanced CKD stages.
Baxdrostat is being evaluated in combination with Farxiga (dapagliflozin) for CKD with cardiorenal risk. This represents AstraZeneca's strategy to build combination regimens targeting the RAAS pathway from multiple angles.
12M US cases/yr · $30.0B 2024 hypertension market
Baxdrostat first-in-class aldosterone synthase inhibitor; dual Phase 3 wins in 2025
Baxdrostat (aldosterone synthase inhibitor) is first-in-class for resistant hypertension. Azelis/AstraZeneca are advancing Phase 3. Existing options include spironolactone and eplerenone. Cardiologist and nephrologist adoption will drive uptake given limited alternatives.
2M US cases/yr · $1.2B Est. addressable market · ~90% Underdiagnosed rate
Primary aldosteronism is the most common cause of secondary hypertension, driven by excess aldosterone production. It is massively underdiagnosed, with most patients treated as essential hypertension. Current treatment includes adrenalectomy for unilateral disease and MRAs for bilateral disease, but MRAs have significant side effects.
Baxdrostat is being evaluated in the Spark-PA Phase II trial for hypertensive patients with primary aldosteronism. As a selective aldosterone synthase inhibitor, it targets the root cause of aldosterone overproduction rather than blocking its receptor.
AstraZeneca completed $1.8B acquisition of CinCor Pharma, gaining baxdrostat, aldosterone synthase inhibitor for treatment-resistant hypertension.
AZ advanced baxdrostat through multiple Phase 3 trials in resistant hypertension and primary aldosteronism targeting large underserved CV market.
FDA approved baxdrostat as BAXFENDY on 18 May 2026 -- first-in-class aldosterone synthase inhibitor for adults with hypertension inadequately controlled on other antihypertensives. Based on the BaxHTN Phase III trial (2 mg: -15.7 mmHg from baseline, -9.8 mmHg vs placebo at week 12). NDA accepted under Priority Review 2 Dec 2025.
Deal thesis realized. Baxdrostat, the asset AstraZeneca paid up to $1.8B for, won FDA approval as BAXFENDY on 18 May 2026 -- the first-in-class aldosterone synthase inhibitor for inadequately controlled hypertension -- on the strength of the BaxHTN Phase III readout. A large underserved cardiorenal market with first-in-class positioning.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / CinCor Pharma Inc. (this deal) | 2023 | $1.8B | 78 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Cardiovascular deals